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or units (normal ward = 13%, ICU = 15%, catheter laboratory or operating room = 62% 
and other = 10%). The average additional cost of any single complication was € 3,438 
(p< 0.01). Life-threatening non-access site bleeding was associated with the highest 
additional costs (€ 47,494; p< 0.05), followed by stage 3 AKI (€ 20,468; p< 0.01), implanta-
tion of a second valve (€ 16,767; p< 0.01) and other severe cardiac dysrhythmia (€ 10,611 
p< 0.05). Interestingly, censoring cases of in-hospital mortality is associated with a 
substantial decrease in the additional costs. ConClusions: Bleeding complications, 
severe kidney failure, and implantation of a second valve are the most important cost 
drivers in TAVR patients, and strategies to reduce those complications may have the 
potential to generate significant in-hospital cost reductions.
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objeCtives: There has been an increase in the number of clotting factor (CF) prod-
ucts available in the U. S. in recent years. Thrombotic events (TEs) are serious adverse 
events that can occur following administration of CFs. The objective of this study 
is to assess the same-day TE risk following exposure to CF products. Methods: 
A retrospective cohort study of individuals exposed to CF products during January 
2008 through June 2013 was conducted using HealthCore Integrated Research Database 
(HIRDSM). CF products were identified by Health care Common Procedure Coding System 
(HCPCS) codes, and TEs were ascertained via ICD-9-CM diagnosis codes. Crude same-
day TE rates (per 1,000 persons exposed) were estimated overall, by congenital clotting 
factor deficiency status and by specific CF products, age, and gender. Results: Of 3,801 
individuals exposed to CFs, 117 (30.8 per 1,000 persons) had TEs recorded on the same-
day as CF exposure. The crude same-day TE rate (per 1,000) was higher for CF users 
without congenital CF deficiency, 70.2 (102 of 1,452), as compared to those with con-
genital CF deficiency, 6.4 (15 of 2,349), unadjusted rate ratio of 11.0 (95% CI 6.4-18.9). For 
individuals without congenital CF deficiency, the crude TE rates (per 1,000) were 15.9 for 
under 15 years of age, 16.1 for 15 to 44 years, 62.8 for 45 to 64 years, and 160.9 for 65 years 
and older. The unadjusted same-day TE rates (per 1,000) ranged from 12.8 for Factor 
VIII to 204.1 for Factor IX complex product(s). Multivariable analyses are underway to 
control for potential confounders and identify recipient risk factors. ConClusions: 
The study shows an increased risk of same-day TEs for CF users without congenital 
CF deficiency and suggests a potentially substantial off-label use of CFs, which needs 
further investigation. In addition, study findings suggest elevated same-day TE rates for 
specific CF products with additional multivariable investigation ongoing.
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objeCtives: Acute myocardial infarction (AMI) is a major cause of mortality 
and disability worldwide. AMI occurs when blood flows irregularly into heart and 
thus heart muscle is injured due to insufficient constant oxygen received. It will 
cause severe complications or co-morbidities if the condition is lasting. Hence, 
we hypothesized the atrial fibrillation (AF) is an independent risk factor to the 
major severe cardiovascular events (MACE) after AMI occurred. Methods: The 
AMI patient is defined by the patient treated in the emergency room at the begin-
ning of the illness. Frequencies and costs of AMI data were extracted from the 
National Health Insurance Research Database for this observational retrospective 
cohort study between 2007 and 2012 in Taiwan. ICD-9-CM 410 was used to extract 
the AMI patients. Fisher’s exact test and categorical data analytic method were 
utilized to assess the AF as a risk factor to MACE in the AMI patients. Results: We 
mainly focused on the AMI adults without any prior MACE occurred. As a result, 
there were 3,452 AMI who can be divided into 2 groups: 2,939 AF patients and 513 
non-AF patients. The average medical cost was USD$ 3142.8 and the mean LoS 
was 10.4 days with st. d. 29.0 days. There were 1,791 MACE identified among the AF 
patients (60.9%), while there were 251 MACE among the non-AF patients (48.9%). 
In consequence, the AMI with AF resulted more MACE than those in non-AF (RR = 
1.63, C.I. = (1.35, 1.97), p < 0.0001). The difference of cost was not significant between 
both groups. The mean LoS in AF was 16.6 days, which was significantly smaller 
than that in non-AF (19.1 days). The difference was probably due to higher fatalities 
in AF. ConClusions: This study has demonstrated that AF risk is associated with 
MACE in patients after AMI occurred.
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bACkgRound: Proactive, post-authorization monitoring of drug safety and effec-
tiveness is of increasing importance. Rivaroxaban is a Factor Xa inhibitor with 
multiple indications, including: treatment of venous thromboembolism (VTE) and 
prevention of recurrent VTE; stroke prevention in atrial fibrillation; and prevention 
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objeCtives: Data are limited on the course of patients after an acute venous throm-
boembolism (VTE) event under clinical practice conditions. Methods: We present 
current data on the re-hospitalization of patients with deep venous thrombosis 
(DVT) or pulmonary embolism (PE) from the PREFER in VTE registry in 7 Western 
European countries (France, Italy, Spain, Germany, UK, Austria and Switzerland). 
The current interim analysis includes data of 2863 patients. 1689 patients had DVT 
alone and 1174 had PE (±DVT) as qualifying event for inclusion. Results: At base-
line, 72.2% of the patients received heparin, 11.9% fondaparinux, 48.0% vitamin K 
antagonists, 25.4% non-VKA oral anticoagulants, 7.0% acetylsalicylic acid, 2.1% other 
antiplatelets and 1.6% thrombolysis agents. Within the first 6 months, 14.7% of VTE 
patients were hospitalized for any reason (DVT: 12.9%, PE: 17.5%). Hospitalization 
rates varied between countries (Spain 10.7%, Germany 10.8%, France 12.5%, Italy 
19.3%, UK (at 3 months) 7.5%). The mean number of hospitalizations was 1.3 ±0.85 
(1.1 to 1.5 in the various countries; median 1, range 1-6). The documented reasons for 
hospitalization, among others, were VTE (15.3%), surgery/trauma (13.5%), bleeding 
(7.4%), or stroke/TIA (3.7%). Mean duration of all combined hospital stays was 9.8 
±12.61 days (4.0 days in Germany,  4.7 in France, 9.0 in Spain, 14.0 in Italy). The overall 
median duration of hospitalization was 6 days (interquartile range 2-12), for DVT 
cases it was 6 days (IQR 3-13), for PE cases it was 5 days (IQR 2-11). ConClusions: 
Under real-life conditions, one in seven patients had to be readmitted to hospital 
in the first 6 months after the DVT or PE event. However, the majority of hospitali-
zations were not due to the thromboembolic disease or bleeding. The duration of 
hospital stays showed a wide range across Western European countries.
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objeCtives: The great majority of patients with atrial fibrillation (AF) require life-
long antithrombotic therapy for prevention of stroke. For optimal treatment, it is 
important to investigate treatment discontinuations, as those might be associated 
with increased hospitalization rates. As potential indicator for unstable anticoagula-
tion efforts we assessed hospitalization rates for non-vitamin K antagonist oral anti-
coagulants (NOAC) and for warfarin under real-life practice conditions. Methods: 
PREFER in AF (The PREvention oF thromboembolic events – European Registry in 
Atrial Fibrillation) is a prospective non-interventional disease registry of patients 
with AF in 7 countries in Western Europe. Discontinuation rates were assessed look-
ing at all patients (n= 6412), whereas hospitalization rates reported at Baseline (BL) 
and 1 year Follow-Up (FU) focused on two groups: patients treated with warfarin 
(BL= 1379, FU= 1571) and patients treated with NOAC (BL= 194, FU= 424). Descriptive 
statistics were applied. Results: Out of 6412 patients, 9 to 18% of patients treated 
with vitamin K antagonists (VKA) discontinued therapy (warfarin 10.3%, phenpro-
coumon 9%, acenocoumarol 10.4%, fluinidone 18%). The discontinuation rates for 
patients on NOAC were 9.4% for rivaroxaban and 10.3% for dabigatran, respectively. 
Reported hospitalization rates (irrespective of reason) were 19.8%/10.0% for NOAC, 
and 24.1%/11.6% for warfarin at BL or FU, respectively. Mean duration of hospitali-
zation was 1.3±4.0/ 0.9 ±5.1 days for NOAC, and 2.0±6.1/ 1.0 ±4.2 days for warfarin.  
ConClusions: No major differences were observed in the discontinuation rates 
between VKA and NOAC on the class level nor the various available NOAC drugs. 
Hospitalization rates and corresponding number of days in hospital reported at BL 
were substantially higher compared to FU. Patients on NOAC had lower hospitaliza-
tion rates and less days in hospital compared to those on warfarin. Further analyses 
are needed to explore the reasons for hospitalizations.
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objeCtives: Transcatheter aortic valve replacement (TAVR) is a relatively new 
alternative to surgical replacement of the aortic valve. Recent development of third 
generation systems and new products have shown reductions in the frequency and 
severity of complications associated with the procedure. The aim of this study was 
to identify the cost impact of complications for patients undergoing TAVR in a German 
hospital. Methods: Data was derived from a prospective observational study, 
whereby a total of 163 consecutive patients were treated either with transfemoral 
(TF-, n= 97) or transapical (TA-) TAVR (n= 66) between February 2009 and December 
2012. Predefined clinical endpoints were analyzed, “in-hospital” costs determined 
from the hospital perspective (2012= 100) and results reported within the seven most 
relevant cost categories. Results: TF-TAVR patients experienced more minor access 
site bleeding (p= 0.017), major non-access site bleedings (p= 0.026), minor vascular 
complications (p= 0.002), stage 2 acute kidney injury (AKI, p= 0.043) and permanent 
pacemaker implantation (p< 0.001) compared with TA-TAVR. However, total in-hos-
pital costs did not differ between groups (mean € 40,348; SD € 15,851). Costs were pro-
portioned in either categories (staff = 26%, materials = 62% and infrastructure = 12%) 
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the opportunity to evaluate several diagnostic workflow from a combined clinical 
and economic perspective using a cost-effectiveness analysis.
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objeCtives: Although apheresis is an important treatment for reducing LDL-C in 
familial hypercholesterolemia (FH) patients, little is known about its treatment pat-
terns. We conducted a systematic review to assess the efficacy/effectiveness, prac-
tice patterns, cost, and clinical guidelines for apheresis in FH patients. Methods: 
Electronic databases were searched for publications of apheresis in FH patients. 
Inclusion criteria include: articles in English published 2000-2013, description of 
practice patterns, efficacy/effectiveness, and costs. Data were stratified by country 
and FH genotype where possible. Results: Thirty-seven studies met the inclusion 
criteria: 8 open-label clinical trials, 11 observational studies, 16 reviews/guidelines, 
and 2 health technology assessments. Of the 19 clinical and observational studies, 
6 assessed only homozygous FH (HoFH) patients, 4 assessed only heterozygous FH 
(HeFH) patients, 6 included HoFH and HeFH patients, and 3 did not specify type of 
FH. The prevalence of FH is not well characterized by country and underdiagnosis 
is a barrier to optimal FH treatment. Apheresis guidelines recommend weekly/bi-
weekly treatments conducted at apheresis centers that may last ≥ 3 hours per ses-
sion. Apheresis may be recommended as first-line treatment in HoFH patients and 
after drug therapy failure in HeFH patients. Studies reported a range of LDL-C reduc-
tion after apheresis: HoFH: 57-75%; HeFH: 58-63%. Eight studies reported apheresis 
costs. Cost (USD 2013) per apheresis session ranged from $2,200-$4,300 in the US, 
$2,150-$2,600 in the UK, $1700-$1850 in Germany and France, and $2,350-$2,750 
in Australia. Calculated annual costs may reach $88,400-$225,000 per patient for 
weekly treatment. ConClusions: LDL-C apheresis treatment is necessary for FH 
patients when drug therapy is inadequate. While apheresis reduces LDL-C, high 
per-session costs and the frequency of guideline-recommended treatment result 
in substantial annual costs. The costs and the inconvenience of apheresis sessions 
are barriers in optimal treatment of FH.
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objeCtives: Our objective was to estimate the impact of catheter-based renal 
denervation plus standard of care (RDN) versus standard of care alone (SoC) on 
European stage-1 hypertension patients with different cardiovascular risk factor 
profiles. Methods: We simulated resistant hypertension cohorts with different 
cardiovascular risk factor profiles (CVRPs) who had stage-1 hypertension despite 
adequate treatment with SoC. Six different cohorts with permutations of starting 
ages of 40, 55, or 70 years; and low and high CVRPs based on JNC7 guidelines were 
modeled. Interventions were RDN plus SoC with three or more anti-hypertensives 
including a diuretic at full doses or SoC alone. As observed in a recent prospective 
uncontrolled pilot study, the impact of a 13 mmHg reduction in systolic blood pres-
sure (SBP) – from a baseline SBP of 151 mmHg – was evaluated. Undiscounted life 
year (LY) and quality-adjusted life year (QALY) gain was computed using a published 
life-time Markov simulation model based on multivariate risk equations. Results: 
Across the studied age groups and cardiovascular risk profiles, catheter-based renal 
denervation was associated with gains in unadjusted (0.51-1.48 LYs) and quality-
adjusted life expectancy (0.39-1.20 QALYs). Younger age and higher cardiovascular 
risk profile led to numerically higher increments. The cohort-specific LY and QALY 
gains were projected as follows: 1) 40 year old cohorts: low CV risk profile: 0.84 LYs/ 
0.78 QALYs; high CV risk profile: 1.48 LYs/ 1.20 QALYs; 2) 55 year old cohorts: low CV 
risk profile: 0.69 LYs/ 0.60 QALYs; high CV risk profile: 1.29 LYs/ 0.95 QALYs; 3) 70 year 
old cohorts: low CV risk profile: 0.51 LYs/ 0.39 QALYs; high CV risk profile: 0.99 LYs/ 
0.68 QALYs. ConClusions: RDN, when used to treat moderate treatment-resistant 
hypertension, is associated with clinically significant increases in life expectancy. 
These model-based findings need to be confirmed in clinical trials.
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objeCtives: The objective of this review was to investigate the use of MIS and intra-
operative imaging technologies in the treatment and management of persons with 
ICH. Methods: A systematic search of the published literature was undertaken in 
February 2014, using the Embase, PubMed and CRD York bibliographic databases. Key 
society websites were also searched for relevant ICH practice guidelines. Studies and 
guidelines reporting on MIS techniques in persons eligible for treatment for Primary 
ICH were included. Results: 1042 citations were retrieved, of which 190 full-text 
articles were reviewed. Six practice guidelines, 4 Systematic reviews, 10 RCTs and 3 
Economic evaluations were included. All 4 systematic reviews of RCT data showed 
consistent results in favour of MIS versus medical management (MM) or craniotomy 
(CR) for both efficacy (mortality and/ or mortality and dependent living benefit) and 
safety (lower rebleeding and higher hematoma volume reduction) vs. CR. A statisti-
cally significant reduction in the relative risk (RR) of death ranging from 34-71% for 
patients treated with MIS as opposed to CR or MM was reported in all 4 reviews. Three 
ICH guidelines (Europe, Japan and USA) recommended the use MIS in specific circum-
of atherothrombotic events (when combined with antiplatelet therapy) following an 
acute coronary syndrome. Use, safety and effectiveness of rivaroxaban in real-life 
settings need to be monitored to understand its value and comply with regulatory 
requirements. objeCtives: To develop a pharmacoepidemiologic PASS programme 
to characterize post-authorization rivaroxaban use and relevant outcomes related to 
safety (intracranial, gastrointestinal, and urogenital haemorrhage) and effectiveness 
(myocardial infarction, ischaemic stroke and thromboembolic events). Methods: 
European sources of longitudinal observational health care data were identified 
that contained population-based data on demographics, comorbidities and co-
medications. Additional studies were designed to capture drug utilization, safety 
and effectiveness data in primary and secondary care via physician questionnaire 
completed based on medical chart review. With an emphasis on the consistent 
definition of endpoints, protocols were developed and tailored for each study for 
submission to regulatory authorities and relevant ethics committees. Results: 
A PASS programme of 7 studies was designed. Rivaroxaban drug utilization, and 
safety and effectiveness, in comparison with standard of care, are being assessed 
using The Health Improvement Network (UK), the PHARMO Database Network (The 
Netherlands), the German Pharmacoepidemiological Research Database and the 
National Swedish Registries. The programme also includes 2 Specialist Cohort Event 
Monitoring studies to collect data on the initial treatment period in secondary care 
settings, and a complementary Modified Prescription-Event Monitoring study that 
evaluates long-term use in primary care. ConClusions: This pharmacoepidemio-
logic PASS programme, with its unique and complementary approach, will monitor 
and characterize the real-life benefit–risk profile of rivaroxaban. A flexible design 
allows the accommodation of any new indications for rivaroxaban approved dur-
ing the study.
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objeCtives: (1) To assess the prevalence of migraine using the National Health 
and Nutrition Examination Survey (NHANES) conducted in the general United 
States population; (2) To calculate the 10-year Framingham cardiovascular dis-
ease (CVD) and coronary heart disease (CHD) risks and compare the risks between 
migraine patients (MP) and non-migraineurs (NM). Methods: MP were identi-
fied using the survey question: “During the past 3 months, did you have severe 
headaches or migraines?” from the 1999-2000, 2001-2002, and 2003-2004 NHANES. 
Independent chi-square tests and t-tests were used to compare differences in 
CVD or CHD risk factors between MP and NM. Multivariant ordinal logistic regres-
sions were used to examine the odds ratios of low, moderate, and high CHD and 
CVD risks between MP and NM accounting for the complex sampling design 
used by NHANES. Significance was defined as p≤ 0.05. Results: Amongst the 
total of 14,204 study subjects (6,731 men and 7,473 women), 2,895 (20.38%) sub-
jects reported having migraines or severe headaches in the past three months. 
The average age of MP was 41.8 (±16.8) years, compared to 47.4 (±19.8) years in 
the NM group. MP had a significantly higher percentage of females, with 1,962 
(67.77%) females. Subjects in the migraine group were found to have an odds 
ratio of 1.208 (95% CI, 1.033-1.412, p-value< 0.001) for moderate CHD risk, and 
an odds ratio of 0.975 (95% CI, 0.732 – 1.412, p-value< 0.001) for high CHD risk. 
Regarding CVD risk, migraine patients were found to have an odds ratio of 1.173 (95% 
CI, 0.818 – 1.683, p-value< 0.001) for moderate risk, and an odds ratio of 1.112 (95% CI, 
0.909 – 1.582, p-value< 0.001) for high risk. ConClusions: Migraine appears to be 
more prevalent among younger subjects with an overall mean age of 42 years old. 
These findings also suggest a positive association between migraine and CHD risks.
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objeCtives: The analysis of different non-invasive imaging strategies in a 
European population of patients with stable angina could help the identification 
of the best approach for the diagnosis of significant CAD. Methods: In 475 pts 
(291 males, 60±9 yrs) with stable angina enrolled in the EVINCI multicenter study, 
CT coronary angiography (CTCA) and stress imaging were performed before inva-
sive coronary angiography (ICA). Significant CAD was defined as > 50% stenosis 
in the left main or > 70% stenosis in a major coronary vessel or 30-70% stenosis 
with fractional flow reserve ≤ 0.8. Nine non-invasive imaging strategies including 
CTCA or stress imaging (ECHO, CMR, SPECT or PET) alone or in combination with 
CTCA performed as first line examinations were evaluated. Combinations were 
positive if both CTCA and the stress test were positive and their performance 
was evaluated in terms of accuracy (AUC). Centres specific reimbursements were 
collected for invasive and non-invasive examination and the costs associated 
with different strategies were obtained at individual patient level by summing 
up reimbursement of the examinations involved. Results: Significant CAD was 
diagnosed at ICA in 140 patients (29%). CTCA had the highest diagnostic perfor-
mance among strategies involving single imaging modalities [0.91 (0.88-0.94)] and 
CTCA-PET among combinations [0.84 (0.74-0.93)]. Costs vary significantly among 
the strategies involving single non invasive modalities with value ranging from 
425 Euro for ECHO to 1245 Euro for PET as well as for those involving combina-
tions of imaging modalities ranging from 508 Euro for CTCA-ECHO to 870 Euro for 
CTCA-SPECT. ConClusions: The diagnostic workflow for CAD detection shows 
variable effectiveness and costs according to the use of different single or com-
bined non invasive imaging modalities. Data collected in the EVINCI study offer 
